April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
SRPK1/2 Inhibition, By SRPIN340, As A Novel Therapeutic To Control VEGF Mediated Choroidal Neovascularisation
Author Affiliations & Notes
  • Melissa V. Gammons
    Physiology and Pharmacology,
    University of Bristol, Bristol, United Kingdom
  • Masatoshi Hagiwara
    Department of Anatomy and Experimental Biology, Kyoto University, Kyoto, Japan
  • Andrew D. Dick
    School of Clinicial sciences and School of Cellular and Molecular Medicine,
    University of Bristol, Bristol, United Kingdom
  • Dave O. Bates
    Physiology and Pharmacology,
    University of Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships  Melissa V. Gammons, None; Masatoshi Hagiwara, None; Andrew D. Dick, None; Dave O. Bates, None
  • Footnotes
    Support  Fight for Sight
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Melissa V. Gammons, Masatoshi Hagiwara, Andrew D. Dick, Dave O. Bates; SRPK1/2 Inhibition, By SRPIN340, As A Novel Therapeutic To Control VEGF Mediated Choroidal Neovascularisation. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5928.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Targeting vascular endothelial growth factor (VEGF), a critical stimulator of both retinal and choroidal neovascularisation, has proven an effective method of treatment in ocular degenerative diseases such as age-related macular degeneration (AMD). VEGF is alternatively spliced producing two families, pro-angiogenic VEGFxxx during proximal splice site (PSS) selection and anti-angiogenic VEGFxxxb when the distal splice site (DSS) is selected. VEGF splice site selection, determined by the binding of splicing factors, is thought to act through separate pathways for PSS and DSS selection. We wished to determine, as serine rich protein kinase 1 (SRPK1) causes the phosphorylation and nuclear localisation of the splicing factor, alternative splicing factor/splicing factor 2 (ASF/SF2), a promoter of PSS selection and pro-angiogenic isoform production, whether inhibiting splicing attenuated choroidal neovascularisation.


SRPIN340, an inhibitor of SRPK1 and SRPK2, was tested in a model of laser-induced choroidal neovascularisation in C57B/6 mice. Subsequent to laser photocoagulation mice received two intraocular injections of 10, 6, 2, 1 or 0.2ng SRPIN340 in the ipsilateral eye and saline in the contralateral eye.


SRPIN340 suppressed choroidal neovascularisation dose dependently in treated eyes with an EC50 of 0.32ng/µl. SRPIN340 also altered the pro-angiogenic to anti-angiogenic VEGF balance in primary retinal pigmented epithelial (RPE) cells switching isoform production from VEGF165 to VEGF165b at the RNA level.


SRPIN340 inhibition of SRPK1/2 appeared to modulate splicing of VEGF to promote anti-angiogenic isoforms. Targeting SRPK1/2 has the potential to prevent VEGF mediated choroidal neovascularisation whilst maintaining the production of cytoprotective VEGFxxxb isoforms.  

Keywords: choroid: neovascularization • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.